USPTO Examiner ADLAM CHANTAL PETA GAYE - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18614993COMPOSITIONS AND METHODS FOR TREATING HYPERTENSIONMarch 2024March 2025Abandon1220NoNo
18090647PHARMACEUTICAL COMPOSITIONDecember 2022January 2025Abandon2421YesNo
18077844SALVINORIN COMPOSITIONSDecember 2022September 2024Abandon2111NoNo
17954557PHARMACEUTICAL COMPOSITIONS CONTAINING PARACETAMOL DERIVATIVES AND USE THEREOFSeptember 2022June 2025Allow3221YesNo
17892620METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 35-64 YEARSAugust 2022February 2025Abandon3020NoNo
17857991COMPOSITIONS AND METHODS FOR TREATING HYPERTENSIONJuly 2022February 2024Allow2010YesNo
1783505118-MC FOR TREATING OBESITYJune 2022June 2024Abandon2520NoNo
17832566BVP8 PROTEIN FOR KILLING TETRANYCHID MITES AND USE THEREOFJune 2022July 2023Allow1400NoNo
17831276USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVEJune 2022June 2024Abandon2420YesNo
17737218RAS INHIBITORSMay 2022September 2024Allow2911NoNo
17614530COMPOSITIONS FOR DELIVERY OF LADOSTIGILNovember 2021March 2025Abandon4010NoNo
17595796FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTSNovember 2021June 2025Abandon4310NoNo
17441082PESTICIDALLY ACTIVE AZOLE AMIDE COMPOUNDSSeptember 2021May 2025Abandon4401NoNo
17458031SYNTHESIS OF POZIOTINIB DERIVATIVEAugust 2021May 2024Abandon3210NoNo
17429968SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5- DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALTAugust 2021May 2025Allow4510YesNo
17428396METHODS AND COMPOSITIONS FOR MODULATING BLOOD-BRAIN BARRIERAugust 2021February 2025Abandon4301NoNo
17415279USE OF OLANZAPINE FOR TREATMENT OF PARP-INHIBITOR-INDUCED NAUSEAJune 2021October 2024Abandon4010NoNo
17325934HETEROCYCLIC COMPOUNDSMay 2021June 2025Allow4911NoNo
17292663CRYSTALLINE FORMS OF A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND AND USE THEREOF AS P2X3 MODULATORMay 2021June 2025Allow4920NoNo
17291547FLAVONOID DELIVERY SYSTEMMay 2021July 2024Abandon3910NoNo
17286799TREATMENT OF NEUROLOGICAL DISEASEApril 2021June 2025Abandon5021NoNo
17281395INDOLE AHR INHIBITORS AND USES THEREOFMarch 2021August 2024Abandon4001NoNo
17276920TLR8 AGONISTMarch 2021April 2024Allow3701YesNo
17276375PROPHYLACTIC AGENT FOR SPONTANEOUS CANCERSMarch 2021March 2025Abandon4830YesNo
17187877LIQUID FORMULATION OF BIPHENYL-CONTAINING COMPOUND AND APPLICATION THEREOFFebruary 2021July 2025Allow5240YesNo
17173069NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASESFebruary 2021February 2024Allow3630NoNo
17265883INHIBITING DEUBIQUITINASE USP25 AND USP28February 2021November 2024Allow4511NoNo
17146327FUROQUINOLINEDIONES AS INHIBITORS OF TDP2January 2021January 2024Allow3711NoNo
17045392TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVESOctober 2020November 2024Abandon4901NoNo
16987092ACRIDINIUM ESTER-CONTAINING COMPOUNDS AND METHODS OF USING THE SAME FOR CHEMILUMINESCENCE-BASED ONE-COLOR SEQUENCINGAugust 2020March 2025Allow5551YesNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner ADLAM, CHANTAL PETA-GAYE - Prosecution Strategy Guide

Executive Summary

Examiner ADLAM, CHANTAL PETA-GAYE works in Art Unit 1622 and has examined 29 patent applications in our dataset. With an allowance rate of 44.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner ADLAM, CHANTAL PETA-GAYE's allowance rate of 44.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ADLAM, CHANTAL PETA-GAYE receive 1.41 office actions before reaching final disposition. This places the examiner in the 31% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ADLAM, CHANTAL PETA-GAYE is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +31.7% benefit to allowance rate for applications examined by ADLAM, CHANTAL PETA-GAYE. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.4% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.